Risk factor
Poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Sartorius AG is a global enterprise specializing in comprehensive bioprocess solutions and laboratory products and services. Its extensive portfolio includes advanced analytical instruments such as biosensors, label-free detection systems, SPR technology, live-cell analysis platforms, and flow cytometry apparatus, complemented by a range of cell analysis reagents and consumables. The company manufactures diverse cell culture media tailored for applications spanning antibody and recombinant protein production, viral vaccine development, regenerative medicine, and stem cell research. It also supplies a variety of general media, downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. Sartorius is a leading provider of bioreactor technologies, offering multi-parallel, benchtop, single-use, stainless steel, cell culture, and microbial models, often integrated with dedicated software applications. A significant portion of its offerings includes a broad array of filtration products: membranes, blotting materials, filter papers, glass and quartz microfibre products, and various filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, buffer exchange, particle analysis, pharmaceutical processes, protein/DNA concentration, venting moisture barriers, and clarification. This segment also features syringe filters, buffer and media products, and membrane chromatography solutions. Further expanding its catalog, Sartorius supplies process filtration and chromatography products, fluid management solutions, process analytical technology with data analytics, industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond products, the company delivers crucial services such as bioprocess development and engineering, protein expression system support, media and process optimization, testing, instrument services, and validation. Serving a wide array of sectors, Sartorius supports life science research, biopharmaceutical manufacturing, quality control and testing, and various applied industries. Established in 1870, this long-standing enterprise maintains its headquarters in Göttingen, Germany.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA